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Cystic fibrosis (CF) is an autosomal recessive genetic disorder involving a mutation in the 
CF transmembrane conductance regulator protein (CFTR), which causes dysfunctional transport 
of chloride ions across cell membranes. CF affects multiple body systems and few of its symptoms 
include chronic cough, difficulty breathing, obstructive airway disease, bacterial pulmonary 
infections, maldigestion, malabsorption, pancreatitis, and male infertility. Until recently, treatment 
options have been limited to alleviating symptoms, but a new classification of drugs, CFTR 
modulators, provide an opportunity to slow the progression of the disease and improve clinical 
outcomes. The effect of CFTR modulators may be attributed to the reduction of persistently 
colonizing bacteria in CF lungs. Though, the effects of modulators on microbial communities 
colonizing the CF lung remains unknown, specifically with common respiratory pathogens such 
as Pseudomonas aeruginosa and Staphylococcus aureus. Particularly, previous CF studies have 
been limited in scope due to focusing on only one type of modulator and by using low-yield 
sequencing techniques. To address this gap, we seek to study the changes in CF respiratory 
pathogens of patients initiating CFTR modulator therapy at Nemours Hospital using long-read 
metagenomic sequencing (Oxford Nanopore) of longitudinally collected respiratory samples. We 
have optimized a protocol for host DNA depletion and microbial metagenomic sequencing to 
characterize the respiratory microbiome. This study focuses on utilizing these sequencing data to 
compare the lung microbiome among two healthy controls to pre-CFTR-treatment microbial 




   
 
iii 
Table of Content 
 
Abstract……………………………………………………………………………………………… Page ii 
List of Figures………………………………………………………………………………………. Page iv 
List of Tables……………………………………………………………………………………….. Page iv 
List of Abbreviations………………………………………………………………………………..  Page v 
Hypothesis and specific aims……………………………………………………………………….. Pages 1-3 
Research design and methods……………………………………………………………………….. Pages 3-7 
Background………………………………………………………………………………………….. Pages 7-10 
Classes of Cystic Fibrosis…………………………………………………………………………… Pages 10-13 
Treatment with CFTR modulators…………………………………………………………………... Pages 14-19 
CF lung microbiome vs healthy lung microbiome………………………………………………….. Pages 19-20 
Effect of CFTR modulators on lung microbiome…………………………………………………… Pages 21-23 
Approaches to characterizing lung microbiome ……………………………………………………. Pages 23-25 
Results……………………………………………………………………………………………….. Pages 25-37 
Conclusion…………………………………………………………………………………………… Page 38 














   
 
   
 
iv 
List of Figures 
 
Figure 1. Airway Surface Liquid Regulation in CF lungs vs. Healthy lungs.  Page 8 
Figure 2. Functional classification of CFTR mutations with examples of more prevalent mutations of 
each class and therapy type. 
Page 11 
Figure 3. Prevalence of the most predominant organisms in the CF lung as a function of age.  Page 20 
Figure 4. The pie chart obtained from MG-RAST shows the percentages of the species found in the 
healthy sample MJ3. 
Page 27 
Figure 5. Bar plot obtained from MJ3 healthy sample which shows the abundance of taxa in order 
from most abundant to least abundant. 
Page 27 
Figure 6. The pie chart obtained from MG-RAST shows the percentages of the species found in the 
healthy sample TA4. 
Page 28 
Figure 7. Bar plot obtained from TA4 healthy sample which shows the abundance of taxa in order 
from most abundant to least abundant. 
Page 29 
Figure 8.A. Krona pie chart for MJ3 that shows the percentage abundance of the organism found in the 
microbiome in a taxonomic order. 
Page 30 
Figure 8.B. Krona pie chart for TA4 that shows the percentage abundance of the organism found in the 
microbiome in a taxonomic order 
Page 31 
Figure 9.A. The pie chart obtained from MG-RAST shows the percentages of the species at genus 
level found in the first CF patient  
Page 32 
Figure 9.B. Bar plot obtained from CF-1 sample which shows the abundance of taxa in order from 
most abundant to least abundant. 
Page 32 
Figure 9.C. The Krona pie chart for the first CF patient (CF-1) that shows the percentage abundance of 
the organism found in the microbiome in a taxonomic order. 
Page 33 
Figure 9.D. Zoomed in cross section of the Krona chart for CF-1 which shows a more detailed 
percentage composition of the Pseudomonas genus.  
Page 33 
Figure 10.A. The pie chart obtained from MG-RAST shows the percentages of the species at genus 
level found in the second CF patient (CF-2). 
Page 34 
Figure 10.B. Bar plot obtained from CF-2 sample which shows the abundance of taxa in order from 
most abundant to least abundant. 
Page 34 
Figure 10.C. The Krona pie chart for the second CF patient (CF-2) that shows the percentage 
abundance of the organism found in the microbiome in a taxonomic order. 
Page 35 
Figure 10.D. Zoomed in cross section of the Krona pie chart of CF-2 showing the abundance of 
Burkholderia cenocepacia with yellow highlights. 
Page 35 
Figure 10.E. Zoomed in cross section of the Krona chart for CF-2 which shows a more detailed 
percentage composition of the Pseudomonas genus.  
Page 36 
 
List of Tables 
 
Table 1. This table illustrates the six CF classes along with mutations in each class Page 11 
Table 2. Human and bacterial DNA qPCR results for healthy-donor sputum samples with and without 
host nucleic acid depletion. 
Page 25 
Table 3. Beta diversity indices for each sample obtained by using Vegan Package in R. The B 
diversities shows that two CF samples are more similar to one another and the two healthy samples are 
also more similar to one another 
Page 37 




List of Abbreviations 
 
CF Cystic Fibrosis 
CFTR Cystic Fibrosis Transmembrane Regulator 
SA Staphylococcus Aureus 
PA Pseudomonas Aeruginosa  
NCH Nemours Children’s Hospital 
WGS Whole-genome sequencing 
IRB Institutional Review Board 
SDI Shannon Diversity Index  
FEV Forced Expiratory Volume  
BCD Bray-Curtis dissimilarity  
MLST  Multi Locus Sequence Typing 
PFGE  Pulsed-Filed Gel Electrophoresis 
ASL Airway Surface Liquids  
FDA Food and Drug Administration  
PPFEV1 Predicted Forced Expiratory Volume in One Second  
FEV Forced Expiratory Volume 
WIMP What’s in My Pot 
MRSA Methicillin Resistant Staphylococcus Aureus 
MG-RAST Metagenomic Rapid Annotations using Subsystems Technology 
CFU Colony Forming unit 
RT Room Temperature 
   
 
1 
Hypothesis and Specific Aims 
 
Cystic Fibrosis is an autosomal recessive genetic disorder involving a mutation in the 
CFTR protein (Cystic Fibrosis Transmembrane Conductance Regulator), which causes 
complications in the lungs, pancreas, and other organ systems and has affected 30,000 people in 
the US (1). The CFTR gene is located on chromosome 7 and codes for CFTR protein, which 
regulates the proper flow of water and chloride ions in and out of epithelial cells lining the lungs 
and other organs; dysfunctional chloride channels affect the transport of ions across cell 
membranes. CF causes variety of symptoms and majority of its effects are seen in the respiratory 
system as it causes frequent coughs, shortness of breath, recurrent lung bacterial infections, and 
chronic sinopulmonary infections leading to lung function decline and shortened life span of CF 
patients (1). Treatment of respiratory bacteria pathogens often requires frequent and continued 
antimicrobial use (2). Until recently, available treatment options have been more directed towards 
alleviating CF symptoms, but a new classification of drugs called CFTR modulators provide an 
opportunity to slow the advancement of the disease for qualifying patients (1). CFTR modulators 
have significantly improved clinical outcomes among CF patients. Some of these impacts may be 
credited to reductions in bacterial colonization and subsequent exacerbation requiring clinical 
intervention. An observational study of CF patients with G551D mutation treated with Ivacaftor, 
a type of CFTR modulator, revealed a 35% reduction in Pseudomonas aeruginosa 
positivity ;however, there were few observed effects on Staphylococcus aureus and other common 
CF pathogens (3). Three other smaller studies assessing the impact of Ivacaftor on the lung 
microbiome of CF patients with G551D mutation have yielded conflicting results (4-6). However, 
these studies have been limited in scope due to targeting only one type of modulator therapy, only 
focusing on select respiratory bacteria, or using poorly resolved methods to assess microbial 
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populations. A second limitation of previous studies pertains to methods for characterizing 
microbiota. To date, majority of studies assessing the CF lung microbiome have used 16S rRNA 
sequencing technique and a few have utilized short-read sequencing with Illumina. Subsequently, 
little is known about the impact of CFTRs on microbial communities colonizing the CF lung or on 
epidemiologically important pathogens such as P. aeruginosa and S. aureus. Further, it is unclear 
whether observed changes to airway microbiology are due to antimicrobial properties of the drug, 
as some evidence has suggested, or because of lung function improvement. This knowledge gap 
may impede clinical decision-making related to modulator therapy in conjunction with 
antibacterial management of respiratory colonizers and pathogens. To address these gaps, we 
sought to study changes in CF respiratory pathogens in patients initiating and maintained on CFTR 
modulator therapy at the Nemours Children’s Hospital (NCH) Pediatric CF Center in Orlando, FL 
using Nanopore metagenomic techniques. The scope of this thesis will focus on the 
characterization of microbial diversity within and between CF patients before they initiate CFTR 
modulator therapy and will compare these findings to healthy samples. These data will later be 
used to investigate how lung microbial communities change after initiation of therapy and how 
these changes are associated with long-term outcomes. Using metagenomic whole-genome 
sequencing (WGS) of microbial communities in the CF lung, we will characterize diversity, 
composition, and evolution (such as any mutations) of these microorganisms over time. Later, 
these changes will be correlated with clinical outcomes. We hypothesize that microbial diversity 
is reduced among patients before the initiation of therapy, with a predominance of select 
opportunistic pathogens in the respiratory flora.  Subsequent studies will test the hypothesis that 
CFTR modulators increase the microbial bacteria diversity by reducing the carriage of common 
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CF bacteria or removal from the lung microbiome. We will test our first hypothesis in the following 
specific aim:  
Aim 1- Characterize the diversity of airway microbial communities among pediatric cystic fibrosis 
patients using metagenomic sequencing. We will test the hypothesis that microbial diversity 
among CF patients is reduced compared to that of healthy controls.   
A.) Assess the microbial diversity (alpha diversity) of CF patients and compare them to healthy 
controls.  
B.) Determine the prevalent species (beta diversity) between CF patients and compare them to 
healthy controls. 
Research Design and Methods 
We propose a prospective, longitudinal cohort study of pediatric CF patients seeking care 
at NCH Pediatric CF center. There are currently 105 patients in the registry of NCH CF clinic out 
of the total 123 pediatric CF patients. 45 patients are already on CFTR modulators and we expect 
the number to increase to 55 by next year (2021). We seek to enroll 10 patients initiating CFTR 
modulator therapy within the following 9-24 months as well as patients that are currently on dual-
combination therapy who qualify for transitioning to triple-combination therapy. Subsequently, 
we will seek to follow the recruited patients for 12 months before and after initiation or change of 
CFTR modulator therapy – allowing for 4 pre- and 4 post-treatment visits Patients already 
receiving triple-combination therapy or who will not be able to be followed for at least 9 months 
prior to starting treatment (3 pre-treatment observations) will be excluded. In addition, patients 
participating in clinical trials that will potentially confound observations of this study will be 
excluded per determination of the clinical lead. This study focuses on the initial characterization 
of the pre-treatment microbial communities of two pediatric CF patients. 
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 Institutional Review Board: The proposal for this study was submitted to be reviewed by the board 
of reviewers at Nemours Children’s Hospital and after an extensive one-year long process, we 
were able to receive IRB approval to initiate this study. 
Data collection: NCH clinical research staff will approach qualifying patients during routine 
quarterly visits and consent will be obtained from parents/children for study. Respiratory samples 
(sputum, throat swabs) collected during routine quarterly visits or Bronchoalveolar lavage 
performed for clinical care will be stored at 4°C and transported to the laboratory of Dr. Azarian 
for processing and sequencing as described below. In addition, respiratory samples and clinical 
isolates collected during acute exacerbations requiring inpatient treatment will be similarly 
processed. Retrospective chart review will be used to identify clinical and microbiological history 
including CFTR mutations, previously identified respiratory bacteria, treatment history, antibiotic 
use, FEV1 values, and frequency of pulmonary exacerbations. Prospectively, for each visit, chart 
review will be used to obtain FEV1 values, frequency of exacerbations, radiology reports, 
antibiotic use, and modulator treatment data. 
Aim 1- Characterize the diversity of airway microbial among pediatric cystic fibrosis 
patients using metagenomic sequencing. Using metagenomic data longitudinally collected from 
patients before modulator therapy, we will test the hypothesis that microbial diversity among CF 
patients is reduced compared to that of healthy controls. We will perform host DNA depletion and 
metagenomic sequencing on respiratory samples collected during the study using an optimized 
protocol as presented in the preliminary data (15). Statistical analysis will be conducted using 
RStudio v1.0.143 with R v3.3.19.  
Host DNA Depletion: Performing ‘host DNA depletion’ is one of the critical steps in our 
methodology since it allows us to focus on the microbial population only. In 2019, Charalampous 
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and colleagues published a protocol for rapid diagnosis of lower respiratory infections using 
Nanopore-based clinical metagenomics, which we now propose to employ here (15). An 
innovative component of their protocol was saponin-based host cell depletion. Working with the 
authors, we have adapted this protocol for use in our laboratory. First, Respiratory sputum samples 
(400µl) will be centrifuged at 8000 xg for 5 min, then the supernatant will be carefully removed, 
and the pellet resuspended in 250µl of PBS. For throat specimens, swabs will be placed in 150µl, 
vortexed and subsequently processed. Saponin which is a detergent used to promote host cell lysis 
will be added to yield a final concentration of 2.2% and incubated at room temperature (RT) for 
10 min. Next, 350µl of water will be added and incubated at RT for 30 seconds. Then, 12µl of 5M 
NaCl will be added to the mixture and samples will be centrifuged at 6000 xg for 5 min, with the 
supernatant removed and the pellet resuspended in 100µl of PBS. Then, 100µl HL-SAN buffer 
will be added, followed by 10µl HL-SAN DNase. The sample will be incubated for 15 min at 37°C 
with shaking at 800 RPM on an Eppendorf Thermomixer for host DNA digestion. Finally, the 
host-DNA depleted samples will be washed two times with PBS (800µl, 1 ml). After each wash, 
the sample was centrifuged at 6000 xg for 3 min, the supernatant discarded, and the pellet 
resuspended in PBS. 
Bacterial growth detection: In order to assess the growth and visualize the type of bacteria in the 
clinical sample, we will plate 100 µl of the sample on each of the following plates: Blood Agar 
(BA), CHROMagar Staph aureus, and CHROMagar Pseudomonas. The plates will be incubated 
for 24 hours and the growth of all 3 plates will be recorded. Then, from each plate three colonies 
will be picked and sub-cultured on new CHROM-SA and CHROM-PA plates. The following day, 
the SA colonies will be verified via Staphyloslide test. Lastly, three isolates from each of the SA 
and PA plates will be stored in -80-degree freezer.  
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Bacterial Lysis and DNA Extraction: After the final wash step of the host depletion, the pellet will 
be re-suspended in 500µl of bacterial lysis buffer, transferred to a bead-beating tube and bead-
beaten at maximum speed (30 oscillations per second) for 3 min in a Tissue Lyser bead-beater to 
ensure the release of DNA from difficult-to-lyse organisms. The sample will be centrifuged at 
20,000 xg for 1 min and ~230µl of supernatant transferred to a fresh Eppendorf tube. The volume 
will be topped-up with 170µl of bacterial lysis buffer and 20µl of proteinase K added. Samples 
will then be incubated at 65°C for 5 min with shaking at 800 RPM on an Eppendorf Thermomixer. 
Lastly, DNA will be extracted from samples using the Qiagen DNeasy Blood and tissue kit 
according to the noted instruction.  
DNA quantification and quality control: DNA quantification will be performed using the high 
sensitivity dsDNA assay kit on the Qubit 3.0 Fluorometer. DNA quality and fragment size (PCR 
products and MinION libraries) will be assessed using the TapeStation 4200 automated 
electrophoresis platform with the Genomic ScreenTape and a DNA ladder.  
Sequencing: Extracted metagenomic DNA will be carried out using the ONT MinION with R9.4.1 
flow cells and MinIT real-time compute module. Library preparation and sequencing will be 
performed according to the manufacturer’s instructions for the Rapid Low-Input by PCR 
Sequencing Kit (SQK-RLI001and Rapid PCR Barcoding Kit (SQK-RPB004).   
Data analysis: ONT MinKNOW software will process raw sequencing data and generate base-
calls. Human DNA reads will be removed from base-called data using Minimap2 to align to the 
human hg38 genome prior to subsequent analysis. The Metagenomic Rapid Annotations using 
Subsystems Technology (MG-RAST) pipeline will be used for analysis of MinION data to identify 
the composition of microbial populations (83). Metagenomic data will be used to determine 
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changes in microbial diversity (alpha-diversity) and composition (beta-diversity) of the respiratory 
microbiome (32).  
Hypothesis testing: Metagenomic data will be used to determine changes in microbial diversity 
(alpha-diversity) and composition (beta-diversity) of the respiratory microbiome as well as 
differences in bacterial growth dynamics and prevalence of antibiotic resistance determinants. 
Alpha diversity values were obtained through MG-RAST and the Vegan package in R was used 
to calculate the Beta diversity between the samples. 
1.) Shannon Diversity Index (SDI, alpha-diversity) – SDI, which accounts for both species’ 
richness and evenness, will be calculated from metagenomic data for each observation (33,34). 
Using a mixed model test for two means in a 2-level hierarchical design, we will compare the SDI 
values (35).  
2.) Bray-Curtis dissimilarity (BCD, beta-diversity) – Compositional differences will be quantified 
using BCD (36, 37).  Significance will be determined using 10,000 permutations of the Mantel 
test, a non-parametric statistical method which measures the correlation between dissimilarity 
matrices (38).  
Background 
The epithelial cells lining the lungs contain a protein on their surface called CFTR, which 
is responsible for the airway surface liquids (ASL) by transporting sodium and chloride ions in 
and out of the cells (7). The ASL has two layers: liquid and a mucous layer. Liquid layer provides 
an environment for the cilia to bath in and the mucous layer traps the bacteria (7). In healthy 
individuals’ lungs, through the movement of chloride ions out of the cells, water is drawn from the 
epithelial cells which leads to hydration of the ASL layers and efficiently removing the bacteria 
by the movement of cilia (7). On the other hand, In CF lungs the hydration of the airway surface 
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liquids is diminished which results in  think and sticky mucus and provides the perfect environment 
for bacterial colonization and infection (7).  
 
Figure 1. Airway Surface Liquid Regulation in CF lungs vs. Healthy lungs. Image obtained from (7). 
Treatment and care to improve quality of life plays a major role in the life of cystic fibrosis 
patients. Since most of the debilitating CF symptoms affect the respiratory system, the main focus 
for treatment options is directed towards improving the respiratory issues. Removing the 
accumulated mucus that is colonized with bacteria is one of the significant steps in decreasing the 
lung inflammation (8). One of the major treatment options for the CF patients in the past 60 years 
has been utilizing antibiotics for bacterial infections, thereby reducing tissue damage from 
inflammation and slowing down the decline in lung function (7). The new advancement in CF 
treatment has been the discovery of a new classification of drugs called CFTR modulators which 
provide an opportunity to slow the progression of the disease for more than 90 percent of patients 
(1). There are multiple CFTR modulator drugs approved by the U.S. Food and Drug 
Administration (FDA), all of which are oral tablets that have the potential to affect not only the 
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lungs but also the sinuses and pancreas. Of the 30,000 persons living with CF in the USA, an 
estimated 15,000 qualify for CFTR modulator treatment and this number is projected to increase 
to 90 % of this population with the approval of triple combination therapy (9). Identifying the 
effects of CFTR modulators on airway microbial communities will facilitate tailoring long-term 
management and more generally elucidate the dynamics of microbial communities in the CF 
airway.  
Currently, there are conflicting data on the dynamics of CFTR modulators and airway 
microbiology. Data are limited largely to a single CFTR-potentiator, Ivacaftor, and studies have 
been limited in sample size, methodology, or scope. For example, microbiome studies have largely 
used only 16S rRNA based profiling, which lacks the resolution of whole-genomic metagenomics 
(4,6). Unlike 16S rRNA based profiling, metagenomics offers the opportunity to study 
communities at the strain level resolutions (11,12). Other studies have focused on specific 
pathogenic bacteria using MLST to PFGE molecular typing (3,6). This limits the ability to 1) 
accurately determine whether the strain present prior to treatment is the same afterwards, 
especially in settings where a common MLST or PFGE is prevalent in the hospital or community 
at large, and 2) assess the pathogen genomic changes in the bacteria that allow it to persist during 
a time of changing lung ecology. Furthermore, culture and molecular diagnostics are unable to 
identify uncommon bacteria and antibiotic resistance mechanisms with high confidence. Here, we 
will overcome these limitations with using nanopore long read technology to enable sampling of 
the microbial communities and the reconstruction and study of the constituent genomes. Nanopore 
sequencing has previously been used in pilot studies to identify bacterial and viral pathogens in 
clinical samples (13-15) as well as rapidly identify antibiotic resistance (16). A major 
methodological advancement has been the recent development of respiratory sample preparation 
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protocols for host nucleic acid depletion, which have allowed nanopore-based metagenomic 
sequencing and analysis (15). Combining single-isolate and nanopore sequencing, we will be able 
to further assess changes in microbial growth dynamics, which is not possible using solely 16S 
profiling data (17). By assessing the growth dynamics of the respiratory microbial community, we 
will be able to assess their physiological status and provide context to the variations observed in 
their composition over time (18). Further, few studies have assessed intrahost adaptation of 
persistently carried respiratory bacteria in CF (e.g., P. aeruginosa (19-20), Burkholderia spp. (21-
25), and S. aureus (25-28)), and none have considered CFTR modulators. In a recent analysis of 
long-term intrahost evolution of S. aureus among cystic fibrosis patients, we found evidence of 
strain adaptations for persistence (29). We will apply the same methodology to investigating 
multiple microbes in the context of intervention. Together, leveraging these advances provides 
significant innovations from prior work. The results from this study will have direct application to 
current treatment practices and lay the foundation for larger multi-center studies. In addition to 
addressing gaps related to modulator treatment, our results will elucidate more general microbial 
dynamics in CF airways as well as have implications for the future use of nanopore-based 
sequencing technology for rapid pathogen diagnostics and antibiotic resistance detection in CF 
patients. 
Classes of Cystic Fibrosis 
To date, more than 2,000 mutations have been found in the CFTR gene that can cause CF 
(30, 69). Over the years, scientists have used several different ways of categorizing these mutations 
into different classes (39). The classical model had organized the CF classes into five categories, 
but the most recent classification system groups these mutations into 6 classes (40, 68). The first 
three classes are more severe and the last three classes are noted to be less severe. 
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Class Type Type of mutations 
Class I Protein production mutations 
Class II  Protein processing mutations  
Class III Gating mutations 
Class IV Conduction mutations 
Class V  Insufficient protein mutations  
Class VI Reduction in CFTR protein stability 
Table 1. This table illustrates the six CF classes along with mutations in each class. 
Figure 2.  Functional classification of CFTR mutations with examples of more prevalent mutations of each class and therapy 
type. Image obtained from (37) 
Class I: Protein Production Mutation             
Class I mutation results from nonsense and splice mutations that preclude synthesis of full-length 
CFTR protein (40). Nonsense mutations in CFTR gene result in an early stop signal that causes 
the termination of production of the CFTR protein which leads to a non-functional CFTR protein 
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(65). Splice mutations interfere with the ability of the cell to correctly read the instructions for 
making the CFTR protein and results in a truncated nonfunctional CFTR protein. Some mutations 
commonly seen in this class are G54X, W1282X, and R553X, and according to the Cystic Fibrosis 
Foundation, 22% of CF patients have the class I mutation (39). 
Class II: Protein Processing Mutations                                                                                                      
Class II mutations include abnormally folded CFTR proteins that are degraded by the cell quality 
control system (38). This is when the CFTR protein is created, but the misfolding does not allow 
it to go to the cell surface. Mutations leading into insertion or deletion of amino acids causes the 
CFTR protein to not form the proper tertiary structure (39,40). Per Cystic Fibrosis Foundation, 
88% of patients have class II mutation and the most common CF mutation F508del is classified 
in this category (39). The F508del mutation removes a phenylalanine amino acid at the position 
508 in the CFTR protein which does not allow the CFTR protein to make the correct tertiary 
structure. Additionally, there are missense mutations that can cause processing problems by 
lowering the quantity of CFTR proteins at the cell surface (39).  
Class III: Gating Mutations                                                                                                                          
Class III mutants are when CFTR reaches the cell surface but due to diminished ATP hydrolysis 
it does not exhibit channel gating (40). The CFTR protein is shaped like a tunnel with a gate 
where cells open the gate when chloride ions need to flow through the channel. Gating mutations 
result in locking the gate and preventing the flow of chloride ions (39, 40). Class III mutations 
are seen in 6% of the CF population (41). 
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Class IV: Conduction Mutations                              
Class IV mutations reduce the chloride ion flow through the channel (40). In order for CFTR to 
function properly, chloride has to move quickly and smoothly through the protein's channel (39). 
Some mutations change the shape of the CFTR protein, thus hindering the movement of chloride 
ions (39). It’s important to note that in class IV mutations, there is a proper CFTR protein that is 
able to reach the cell surface, but the function of the channel is faulty due to reduced chloride 
conductance (40, 43). 6% of CF population has been noted to have Class IV mutation and some of 
the common mutations in this class are D1152H, R347P, and R117H (43). 
Class V: Insufficient Protein Mutations          
Class V mutations cause a decreased quantity of CFTR protein at the cell surface. Several reasons 
can lead to this such as: alternative splicing, production of a limited amount of CFTR proteins, and 
a low number of properly working CFTR proteins at the cell surface (39). Insufficient quantities 
of functional proteins at the cell surface leads to transportation of fewer chloride ions in and out 
of the cell linings (66). Class V mutations account for 5% of the CF population (39). 
Class VI: Reduction in CFTR proteins stability                        
Class VI mutants result in instability of CFTR at the plasma membrane by reducing its 
confirmational stability (67). In this mutation, the CFTR at the plasma membrane is removed and 
sent to lysosome during recycling (40, 42). rF508del and Q1412X are couple of mutations found 
in this class. 
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Treatment with CFTR modulators 
CFTR modulators target the main defect in the CFTR mutation. There are several modes 
of action of CFTR modulators, but their main goal is to restore the wild type CFTR protein or at 
least to modulate the mutant protein and improve their functionality (44,45). CFTR modulators 
have shown to have significant clinical benefits such as improvements in weight, growth, lung 
function and lowering the risk of pulmonary exacerbations (54). CFTR modulators are commonly 
referred to as ‘personalized’ treatment since each type of modulators are prescribed to patients 
with a specific mutation that the modulator has been designed for. Currently, there are four groups 
of CFTR modulators approved by the U.S. Food and Drug Administration (FDA). The modulators 
are in a form oral tablets and have the potential in improving the lung function as well pancreas 
and sinuses (46).   
Classification of CF mutations in 6 distinct classes is advantageous in making a 
corresponding classification for CFTR modulators designed for repairing the defects in each 
mutation class (47, 66). The CFTR mutation in each class leads to a different dysfunctional 
etiology and thereby different CFTR modulator types are developed to address each of the 
etiologies. The first three classes of mutations are considered ‘severe’ in that they are associated 
with little or no protein function at the epithelial surface and due to affecting a larger pool of CF 
patients, they have been the priority in developing CFTR modulator therapies for (48).  Following 
are the main types of CFTR modulators: 1) Potentiators. 2) Correctors. 3) Amplifiers. 4) “Next 
Generation” 
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1. Potentiators                 
 In January 2012, FDA approved the first CFTR modulator called Ivacaftor (Kalydeco), a 
type of potentiator. Potentiators bind and potentiate the opening of CFTR protein at the cell surface 
and help chloride ions flow through the CFTR protein channel (49). Ivacaftor is designed for 
patients with Class III and Class IV mutations. Class III are gating mutations in which altered 
protein at the membrane surface has locked the gate; therefore, ‘potentiators’ hold the gate on the 
CFTR protein and allow chloride ions to flow through (10). Ivacaftor is also used in individuals 
with G551D mutation found in Class II and involves 4% of CF patients. Recently, ivacaftor was 
approved by the FDA for another eight gating (Class III) mutations which together with G551D 
account for total of ~5% of all CF patients (50). Due to its mechanism of action, ivacaftor is 
effective only in patients who have some degree of functioning CFTR protein production. Thereby, 
Ivacaftor is not suitable for patients who have the homozygous F508del mutation or any mutation 
classes that entirely prevent the production of the CFTR protein (55). Ivacaftor was approved after 
achieving promising results from various studies, with the focus of one of the studies being patients 
6 to 11 years old. Davies and collogues performed a randomized, double-blind, placebo experiment 
with patients of ages 6–11 with a G551D mutation on at least one allele (56). Fifty-two patients of 
6 years or older were randomly given either ivacaftor or placebo. During the treatment patient’s 
forced expiratory volume (FEV1) which is the amount of air the patient can exhale in one second 
was measured to test their lung function. Patients with chronic obstructive lung diseases or CF 
patients tend to have lower FEV values. Percent predicted forced expiratory volume in 1 second 
(ppFEV1) results after 24 weeks of treatment indicated that ivacaftor caused a 12.6% increase 
from baseline in comparison to a 0.1% increase seen in the placebo group (59). Per study results, 
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Ivacaftor reached its more significant effect on improving the lung function by day 15 of the 
treatment and the improvement continued through week forty-eight (56).  
2. Correctors                
 Correctors were designed to facilitate the CFTR protein processing and increase the 
quantity of CFTR protein at the plasma membrane. They are two types of correctors: Lumacaftor 
and Tezacaftor. Correctors aid in forming the correct tertiary shape of the CFTR protein so the 
protein is able to reach the cell membrane and transport chloride. Correctors are an appropriate 
treatment choice for patients with class II CF mutations (10). F508del mutation, one of the most 
common CF mutations belongs to Class II mutation. Almost half of the CF patients who have two 
copies of the F508del mutation are qualified to take the ‘corrector’ modulator therapy (10). Data 
obtained from initial in vitro testing, indicated that lumacaftor could assist the “trafficking” of 
CFTR protein and allow the proteins to reach the cell membrane and transport chloride ions (57).  
In a subsequent phase 2a study, eighty-nine CF patients with homozygous F508del 
mutation were randomly assigned to either receive placebo or one daily dose of lumacaftor four 
weeks (58). People with CF have more chloride in their sweat than healthy individuals, therefore 
sweat chloride test is one of the golden tests for CF. In this study, Lumacaftor demonstrated a 
significant mean difference in sweat chloride testing in the experiment group compared to placebo 
(49). Lumacaftor had positive effects on sweat chloride test, but it did not have significant effect 
on the respiratory symptoms, the lung function, and FEV1 by itself (49). There is another corrector 
called tezacaftor which functions similarly to lumacaftor by allowing the CFTR protein make the 
right tertiary shape, traffic to the cell surface, and stay there longer. 
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Combining Two Modulators 
After achieving not very impressive results with implementing Lumacaftor and Ivacaftor 
alone to treat the homozygous F508del CF patients, scientists decided to combine these two 
modulators (49). In July 2015, the FDA approved the lumacaftor/ivacaftor (Orkambi) combination 
therapy which is developed for patients 2 years and older who have two copies of the F508del 
mutation (52, 55). The rationale behind combining these two modulators is that lumacaftor will 
help with the trafficking of the CFTR protein, and ivacaftor will assist the CFTR protein to remain 
open and transport chloride ions. In some situations, the proteins that do reach the cell surface do 
not open adequately to allow chloride to pass out of the cell; in this case, utilizing a corrector 
mixed with a potentiator to hold the gate open allows enough chloride to flow through the channel 
to reduce the symptoms of CF.  
The combinations of lumacaftor/ivacaftor (Orkambi) and tezacaftor/ivacaftor (Symdeko) 
are utilized in treating people with homozygous F508del mutation (10, 53, 55). 
Tezacaftor/ivacaftor combination is also approved for treatment of people ages 6 and older with a 
single copy of one of 26 specified mutations published on the CF foundation (10). Per CF 
foundation, patients treated with tezacaftor/ivacaftor in clinical trials showed a 6.8% improvement 
in the lung function (10). The difference between the two approved combinations is that the 
tezacaftor/ivacaftor combination has been reported to have fewer side effects and drug interactions 
than lumacaftor/ivacaftor (51).  
3. Amplifiers          
 Amplifiers are currently being developed and tested and are not yet available. The goal of 
amplifiers is increase quantity of the produced CFTR proteins. Amplifiers could be used in 
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combination with potentiators and correctors to further improve the function of CFTR protein and 
allow even more chloride to flow across the cell membrane (10).  
4. “Next Generation”                      
 Ivacaftor and lumacaftor were approved first; therefore, they are more commonly referred 
to as “first-generation modulators”. Tezacaftor, approved in February 2018, is also considered a 
first-generation modulator. “Next-generation” modulators are the newer and potentially the more 
effective CFTR modulators. The next-generation CFTR modulators focus on various problems 
caused by the F508del mutation to improve CFTR folding and increase the amount of CFTR 
proteins reaching the cell surface (10). The objective behind designing the “next generation” 
modulators is to develop drugs that can be approved for the CF patients that could have not 
benefitted from the previous modulators including individuals with a single F508del mutation (10, 
39). VX-659 and VX-445 are two types of “next-generation” correctors with a different structure 
and mechanism of action than the first-generation correctors lumacaftor and tezacaftor (59, 60). 
The goal of “next generation” modulators is to be able to be used in treating the CF patients that 
were previously not qualified for any other modulators. Scientists have shown that the combination 
of next generation modulators with correctors is better at increasing the quantity of CFTR proteins 
at the cell surface that solely using correctors (59, 60). 
Triple Combination Therapy 
As of October of 2019, the FDA has approved the use of Trikafta, which is a triple 
combination therapy for treatment of CF that could potentially treat 90% of the patients (64). Per 
Dr. Jeffrey Leiden, president and CEO of Vertex Pharmaceutical, Trikafta is the first medication 
that can treat the underlying cause of the disease for about 6,000 patients (65). These triple drug 
combination therapies along with next-generation CFTR correctors target the patients with only 
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one F508del mutation (62). Since 90% of the CF patients have at least one copy of F508del 
mutation.  
Triple combination is when the two next generation correctors: VX-445 and VX-659 are 
each used in combination with tezacaftor and ivacaftor (61). Trikafta was approved after a two 
Phase 3 trials in the AURORA program. This study included more than 500 CF patients of ages 
12 and older (63). Data from both studies showed significant improvements in lung function 
(ppFEV1) in patients given Trikafta. The first study tested VX-445 combined with 
tezacaftor/ivacaftor (Symdeko) in CF patients of 12 years and older who had only one copy of the 
F508del mutation. After 28 days of treatment the results indicated a 13.8 percent increase in lung 
function compared to the placebo group (65).  
The second study wanted to test the effectiveness of tezacaftor/ivacaftor alone compared 
to VX-445 combined with tezacaftor/ivacaftor. In this study CF patients of 12 year and older with 
two copies of the F508del mutation participated. Following 28 days after treatment, participants 
who received the triple combination had a 10 percent improvement in lung function compared to 
those who only received the tezacaftor/ivacaftor (62, 63). Approval of Trikafta is a significant 
milestone for the CF community since now more CF patients will be qualified for treatment with 
CFTR modulators that could greatly benefit their health, decrease the CF symptoms, and improve 
their quality of life. 
CF lung microbiome vs healthy lung microbiome 
Historically, it was believed that the lung is sterile. However, decades of respiratory 
culture-independent protocols for bacterial identification and high throughout sequencing 
techniques has debunked this myth (71). Healthy lung microbiome prominently consists of 
Proteobacteria, Firmicutes, and Bacteroidetes at the phylum level and Pseudomonas, Prevotella, 
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Fusobacteria and Veillonella at the genus level (70). CF is one of the chronic lung diseases that 
the disease course is significantly influenced by the changes in the composition of the lung 
microbiome (71). Thereby, in the absence of the normal lung microbiota, the patient is more 
susceptible to bacterial infections with organisms such as Listeria monocytogenes and Klebsiella 
pneumonia (72, 73).  
 Most common pathogens in the CF lungs include P. aeruginosa, S. aureus, B. cepacia, H. 
influenza, S. maltophillia, and MRSA (7, 70). According to the British Society for Immunology, 
the lungs of about 50% of CF patients during infancy are predominantly occupied by 
Staphylococcus aureus, which continues to decline as the patient gets older (7). By the age of 18, 
gram negative Pseudomonas aeruginosa becomes the bacteria predominantly colonizing the CF 
lungs in about 80% of patients (7). Out of all of the pathogens in the CF airway, P. aeruginosa is 
the one most strongly correlated with causing respiratory decline (75). Therefore, it is critical to 
gain a more precise understanding of the effect of restoring the CFTR function on the presence or 
absence of P. aeruginosa. 
 
Figure 3. Prevalence of the most predominant organisms in the CF lung as a function of age. Obtained from 74. 
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Effect of CFTR modulators on lung microbiome 
To date, there have been a few small cohort studies that focused on assessing the changes 
in the lung microbiome of CF patients after treatment with a modulator; thereby the data available 
are limited. In the paper published in 2015 by Bernarde et al, they assessed the airway of three 
pediatric CF patients, with G551D mutation treated with Ivacaftor, by utilizing qPCR and 16s 
rRNA sequencing (4). Important note is that none of the patients had chronic Pseudomonas 
aeruginosa infection and they were followed for 13 months after the initiation of the treatment. 
The analysis showed that no significant changes were identified before and after the treatment (4).  
Another longitudinal study was done in 2012-2013 in G551D CF patients of 6 years and 
older that were being treated with Ivacaftor (5). 133 patients with known P. aeruginosa infection 
completed this study, and they were assessed at the baseline and then at 1, 3, and 6 months 
following the Ivacaftor treatment. The analysis showed improvement in FEV1 %, body mass, 
sweat chloride testing, and mucociliary clearance. They also noted a significant reduction in the 
detection of P. aeruginosa infection 6 months after starting the therapy (5, 75). To gain a more 
comprehensive analysis, the researchers performed a P. aeruginosa-specific qPCR, which didn’t 
indicate a significant decrease in sputum abundance. They also performed a sputum inflammatory 
marker test and microbiota analysis by 16S sequencing on 14 patients. The findings showed a 
combination of traditional CF bacteria and no significant changes in the bacterial diversity nor in 
the inflammatory markers were noted after the Ivacaftor treatment (5, 75). However, the interesting 
finding was the overall downward trend of the combined abundance of the traditional CF microbes 
and an increase in the abundance of Prevotella, which is one of the bacteria commonly colonizing 
the healthy lungs (75).  
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A subsequent study in 2016 by Hisert et al. included 12 adult CF patients with G551D 
mutation and chronic airway infection who were qualified for Ivacaftor therapy (6). Patients were 
followed longitudinally and 16S sequencing of sputum bacteria content, lung CTs, lung function, 
and inflammatory marker tests were done before and after the initiation of Ivacaftor therapy (6). 
Eight of the patients in this study had chronic P. aeruginosa infections. It was noted that the P. 
aeruginosa content in their sputum sample began decreasing at day 2 and the average number of 
colonies forming units (CFUs) of P. aeruginosa decreased by 10-fold by day 7 of the study (6). 
The analysis of the microbiome also indicated a general decrease in the abundance of P. 
aeruginosa, with an increase in the abundance of the nontraditional CF organisms such as 
Streptococcus, Prevotella, and Veillonella (6). Though, the interesting finding to note is that none 
of the patients in the study became consistently negative for P. aeruginosa infection, and after the 
first year of the study the density of P. aeruginosa rebounded (6). 
 In a following study in 2016-2017 Peleg et al focused on investigating the effect of 
Ivacaftor on CF lung microbiome during the early treatment period (76). Twenty G551D CF 
patients participated in this double blind, placebo, crossover study of Ivacaftor for the first 28 days 
of treatment. Sputum microbial content was assessed with 16S rRNA sequencing and qPCR 
techniques and the clinical symptoms were tested via respiratory function and blood testing (76). 
The findings indicated no significant changes in total load of P. aeruginosa and no changes in the 
composition of the lung microbiome during treatment with Ivacaftor in comparison to the pre-
treatment lung microbiome (76). But they noted that over time the sputum microbiome variation 
was greater between subjects that within them (75, 76). Thus far, studies that have focused on 
assessing the CF lung microbiome have been done using the less-resolved techniques such as 16S 
rRNA sequencing, thereby, the data gathered are inconsistent and limited. Therefore, 
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understanding the impact of CFTR treatment on the CF lung microbiome with more advanced 
techniques is critical to inform of the CF community of both the function of the modulators and 
also help the physicians in strategizing treatment plans to manage the CF infections with 
modulators in conjugation to antibiotics. 
Approaches to characterizing lung microbiome 
There are various methods available for sequencing samples such as 16s rRNA:  
pyrosequencing, Illumina, and ONT MinION. The factor that adds to the significance of our study 
is using Nanopore based sequencing technique for metagenomic analysis of the microbiome, 
which has never been done before on CF lung microbiome. Most common technique used for 
analysis of CF microbiome has been the 16s rRNA sequencing technique which takes advantage 
of the 16S rRNA housekeeping genes on the 30S ribosome subunit as a genetic marker. This is 
due to being present in almost all bacteria and having a large enough size for informatics purposes. 
However, the 16S rRNA technique is limited due to short read lengths, sequencing errors, limited 
resolution, and the difficulty in assessing the diversity according to a single gene marker (80). 
Illumina sequencing is one of the Next Generation Sequencing (NGS) technologies. 
Illumina sequencing generates high throughput data with high accuracy rate of 99%. The data 
outputs short length reads and depending on the type of the platform used the read length can reach 
300 base pairs in each run. Illumina follows a sequencing by synthesis (SBS) approach, which 
detects each of the bases as they are added to the growing DNA chain (77). Illumina sequencing 
is done simultaneously on every cluster on a flow cell which is a solid surface with millions of 
different molecules (81). The Illumina sequencing method is similar to Sanger sequencing except 
it uses dNTPs with a reversible terminator block that blocks further polymerization so only one 
nucleotide can be added by the polymerase (81). In SBS each of the reversible terminating 
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nucleotides are fluorescently labeled with a different color and attached to a different fluorophore 
for easy identification as they pass the flow cell (77).  First, the primer anneals to its 
complementary strand and DNA polymerase begins making a copy of the DNA using the 
fluorescently labeled nucleotide blocks. The fluorophores act as a blocking group in a way that 
DNA polymerase cannot add a new base until the fluorophore is removed (77). Once the 
fluorophore for the added base is recorded by the computer, the fluorophore is removed, and DNA 
polymerase resumes its activity. Although the Illumina technology is able to detect the variants 
that were missed in the traditional Sanger sequencing, it has a major disadvantage of outputting 
short length reads, which makes it difficult to complete the whole genome (79). 
Another type of sequencing technology, which is the method utilized in this study, is Oxford 
Nanopore technology (ONT), which is one of the newest and most powerful method of rapid 
generation of sequencing data. The advantage of nanopore sequencing data is that the read length 
(fragment length of DNA) is significantly longer than the more commonly used Illumina (2,500-
70,000 bp compared to 100-300 bp), which we can use to identifying species level data as well as 
the presence of genes of interest (e.g., antibiotic resistance genes) with high confidence. 
Additionally, it is portable, the cost is affordable, and only requires a computer to analyze the data 
(82). Some of the disadvantageous of Nanopore are its lower throughput and lower accuracy read 
compared to Illumina with accuracy rate of 92-97% (82). Nanopore follows a direct sequencing 
method. It has biological pores that are inserted into a synthetic polymer membrane which is 
immersed in an electrolyte solution that generates an ionic current through the pores (82). As 
molecules enter the nanopore, the DNA pauses temporarily in one nucleotide interval. During this 
pause, the MinION identifies the nucleotides bases according to the changes that they cause in the 
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current of the nanopores (78). The nucleotides are characterized, and the data streams are then 
passed through the software that generate the data.  
Results 
We recruited two healthy individuals to participate in our study. We performed five 
replicates of host-depletion on healthy respiratory samples from sputum and oropharyngeal 
swabs obtained from two individuals (MJ and TA), varying microbial cell-lysis approaches.  
Probe- and SYBR-Green-based qPCR was performed on undepleted and depleted samples to 
quantify human DNA and the bacterial 16S rRNA V3-V4 gene fragment. In all five replicates, we 
observed 10 to 50-fold depletion of host DNA with minimal loss of microbial DNA. We selected 
two samples, MJ3 (sputum) and TA4 (oropharyngeal) for nanopore-based sequencing, producing 
1.87 and 1.72 gigabases of data for MJ3 and TA4, respectively (read length N50 3,400 bp). After 
de-multiplexing and filtering reads by quality and length, reads were mapped to the human 
reference genome hg38, and unmapped microbial reads were exported for subsequent analysis.  
For MJ3, 76% of reads (1.43 Gb) were microbial; for TA4, 96.5% (1.67 Gb) were microbial. 
Microbial reads were analyzed using the EPI2ME WIMP (What’s in my Pot) pipeline (31).  For 
MJ3, 29 genera were identified at a relative abundance level greater than 0.1%, dominated by the 
genus Streptococcus, and 28 species were classified at an abundance >0.5%.  For TA4, 29 genera 
Table 2. Human and bacterial DNA qPCR results for healthy-donor sputum and throat swab samples with and without host 
DNA depletion. 
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were also identified with an abundance >0.1%, dominated by the genus Prevotella, and 40 species 
were classified at a relative abundance >0.5%. We demonstrate successful depletion of host DNA 
followed by nanopore based metagenomic sequencing to characterize the airway microbiome. 
Additionally, the raw sequencing data were uploaded on MG-RAST which is an open-source web 
application built for performing quality control, analyzing, and annotating metagenomic results. 
MG-RAST automatically assigns functional sequences that belong to the metagenome by 
performing comparison to datasets and then provides phylogenic trees, bar plots, and graphs of 
the analyzed metagenome (83). We obtained pie charts and bar plots from MG-RAST which 
provided information about the abundance of the species in each sample. Figure 4 is a pie chart 
obtained from MG-RAST which shows the most abundant species found in the healthy sample 
MJ3. As seen in the pie chart, Streptococcus with 40.29% is the most abundant organism in this 
individual, followed by Prevotella with 15.76%, Fusobacterium with 10.24% and Veillonella with 
6.27%, which are all the organisms commonly found in healthy lung microbiome. Per MG-RAST, 
the dataset for MJ3 contains 468,700 sequences totaling 1,425,422,904 base pairs with an average 
length of 3,041 bps. The alpha diversity for this set if 90 species. 




Figure 4. The pie chart obtained from MG-RAST shows the percentages of the species found in the healthy sample MJ3. 
MG-RAST also provided bar plots showing the most abundant taxa in order. Figure 5 is the bar 
plot for MJ3. The bar plot here shows the same results indicated in the pie chart, with Streptococcus 
having the highest abundance followed by Prevotella. 
 
 Figure 5. Bar plot obtained from MJ3 healthy sample which shows the abundance of taxa in order from most abundant to least 
abundant. 
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Similar figures were obtained from MG-RAST for TA4, the second healthy sample. The pie chart 
provided for TA4 (Figure 6) illustrates Prevotella with occupying 28.55 % of the composition is 
the most abundant organism in this sample followed by Streptococcus with 23.98%. The bar plot 
for TA4 (Figure 7) also demonstrated Prevotella to have the highest abundance followed by 
Streptococcus in a close margin. This dataset contains 476,322 sequences totaling 1,668,623,029 
base pairs with an average length of 3,503 bps. The α-diversity of this data set is 80 species. 
Comparing the two healthy sample, we can conclude that they both are occupied by organisms 
expected to be found in healthy lung microbiomes. Additionaly, the alpha diversity which 
measures both richness and evenness within each sample was reported. As species richness 
increases so does the alpha diversity. The alpha diversity for MJ3 is 90 and for TA4 is 80, which 
are relatievly close to one another and higher that then diversities obtained for the CF patients 
which supports the hypothesis that diversity within CF patients is lower in compariosn to healthy 
individuals. 
 
Figure 6. The pie chart obtained from MG-RAST shows the percentages of the species found in the healthy sample TA4. 




Figure 7. Bar plot obtained from TA4 healthy sample which shows the abundance of taxa in order from most abundant to least 
abundant. 
 
 The most abundant species in MJ3 is Streptococcus with 40.29% and the most abundant organism 
in TA4 is Prevotella with 28.55%. An interesting observation is that in MJ3, the most abundant 
organism, Streptococcus, is occupying a significant portion of the microbiome. And there is a 
noticeable difference between composition of Streptococcus with 40.29% and the second most 
abundant organism, Prevotella, with percentage of 15.76. Same observation cannot be made for 
TA4, since the percentages of the composition of each organism in TA4 sample’s microbiome are 
a lot closer to one another, with the most abundant organism, Prevotella, occupying 28% of the 
lung microbiome and the second most abundant organism occupying 23% of the composition. We 
also obtained Krona charts for each of the sample. Krona is a visualization tool that allows for 
hierarchical data to be shown in multi-layered pie charts (84). The Krona resembles a pie chart, in 
which the chart subdivides each class into a sector which is overlaid with smaller sections that 
represent the constituents of the previous sector (84). Here, the Krona pie charts obtained are 
following a taxonomix hierarchy in which the first section in the middle of section is starting from 
Bacteria, and then as we go up from the middle circle we see the domain, phylum, class, and lastly 
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genus level species. Figure 8.A represents the Krona pie chart for MJ3 and figure 8.B represents 
the Krona chart for TA4. The Krona charts follow a taxonomic order, with Firmicutus being the 
most abundent at the phylum level in both samples. We know from the MG-RAST data that 
Streptococcus is the most abundent organism in MJ3, and by further analyzing the data with the 
Krona chart, we can conclude that within the genus of Streptococcus, the most abundant species 
is Streptococcus parasanguinis with 9% abundance.  
 
 Figure 8.A. Krona pie chart for MJ3 that shows the percentage abundance of the organism found in the microbiome in a 
taxonomic order. 
 




 Figure 8.B. Krona pie chart for TA4 that shows the percentage abundance of the organism found in the microbiome in a 
taxonomic order. 
The Krona pie chart obtained for TA4, indicates Firmicutes to have the highest abundancein 
phylum level. In the species level, Prevotella melaninogenica is shown to have the highest 
abundancewith 12%. 
Similar analyses were done to obtain pie chart, bar plots and krona charts for the two CF 
samples. Figure 9.A shows the pie chart obtained from MG-RAST for the first CF patient (CF-1), 
which notes Prevotella to be occupying the most of the lung microbiome (45.05%), followed by 
Streptococcus (26.50%), and then Veillonella (11.66%). The bar plot (Figure 9.B) also shows 
Prevotella to be the leading taxa with the highest abundance. The Krona chart becomes very useful 
here (Figure 9.C) because we were able to zoom in and look more in detail into the species level. 
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The first CF patient that we obtained throat swabs from had known history of Pseudomonas 
Auroginosa infection and by zooming into the taxonomy level in the Krona chart we were able to 
find Pseudomonas that is occupying 5% of the patient’s lung microbiome. Also, after careful 
analysis into the genus level organisms and further looking into the Pseudomanas genus, we 
noticed Pseudomonas aeruginosa species to be occupying 18% of the Pseudomanas genus (Figure 
9.D) 
 
Figure 9.A. The pie chart obtained from MG-RAST shows the percentages of the species at genus level found in the first CF 
patient (CF-1). 
 
Figure 9.B. Bar plot obtained from CF-1 sample which shows the abundance of taxa in order from most abundant to least 
abundant. 




Figure 9.C. The Krona pie chart for the first CF patient (CF-1) that shows the percentage abundance of the organism found in 
the microbiome in a taxonomic order. A * is put next to Pseudomonas species for ease of detection.      
           
 
 Figure 9.D. Zoomed in cross section of the Krona chart for CF-1 which shows a more detailed percentage composition of the 
Pseudomonas genus.  
* 
* 
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The pie chart obtained from MG-RAST and the bar plot for the second CF patient (CF-2) were 
analyzed. The most abundunt organism in CF-2 is Prevotella (53.47%) followed by Veillonella at 
17.03% and then Streptococcus with 8.75%. 
 
Figure 10.A. The pie chart obtained from MG-RAST shows the percentages of the species at genus level found in the second CF 
patient (CF-2). 
 
Figure 10.B. Bar plot obtained from CF-2 sample which shows the abundance of taxa in order from most abundant to least 
abundant 
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Figure 10.C. The Krona pie chart for CF-2 that shows the percentage abundance of the organism found in the microbiome in a 
taxonomic order. 
 
Figure 10.D. Zoomed cross section of the Krona pie chart of CF-2 showing the abundance of Burkholderia cenocepacia with 
yellow highlights. 
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When analyzing the lung microbiome of the second CF sample which was obtained from 
a 2-year old male patient’s oropharyngeal swab, the krona pie chart provided a detailed look into 
the species level of the organisms. In the initial glance, Bacteroidetes has the highest abundance 
in the phylum level followed by Firmicutes. After further investigation into the Proteobacteria 
phylum and the Betaproteobacteria class, we found 1% composition of Burkholderia which is one 
of the microbes known to cause infections in the CF lungs. Additional analysis into Burkholderia, 
we indicated Burkholderia cenicepcia occuppying 8% of the whole Burkholderia genus (Figure 
10.D). This patient (CF-2) also noted to have Pseudomonas genus occupying 1 % (Figure 10.E) 
of his lung microbiome, with Pseudomonas aeruginosa occupying 21% of the Pseudomonas genus 
(Figure 10.E) 
 
Figure 10.E. Zoomed in cross section of the Krona chart for CF-2 which shows a more detailed percentage composition of the 
Pseudomonas genus. The pie chart on the left shows the Pseudomonas abundance. The Chart on the right is the shows the 
abundance of Pseudomonas Aeruginosa species within the Pseudomonas genus. 
Subsequently, MG-RAST was used to find the alpha diversity values for the CF samples. 
CF-1 had alpha diversity of 43 and CF-2 had alpha diversity of 45. These values are significantly 
* 
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lower than the alpha diversity indices obtained for the healthy samples which were 80 and 90 for 
MJ and TA consecutively. This illustrates that the diversity of the lung microbiome decreases 
significantly in CF lungs pre-CFTR treatment in comparison to healthy lungs. Beta diversity 
measures the changes in the composition between the two samples and is commonly measured 
with Bray-Curtis dissimilarity index. In Bray-Curtis, the values outputed are between 0 and 1. 
Values close to 0 mean that the samples are identical or that they share the same species; and 
values closer to 1 mean that the samples having nothing in common. Table 2 shows the Beta 
diversity indices between each of the sample. As seen the Beta diversity index between the two 
healthy samples is 0.23, which inidicates that these two samples share similar species composition. 
The Beta diversity between the two CF samples is calculated to be 0.31, which also suggests that 
these two CF samples are more similar to one another. When comparing CF to healthy samples, 
we see that the beta diversity between them is higher than the within group comparison, showing 
that there is more dissimilarity in species composition between CF and healthy samples (Table 3).  
This pattern is somewhat expected, since there is more similarities when comparing one healthy 
lung microbiome to another healthy one, as oppose to comparing the CF microbiome composition 
to healthy ones. 
 TA4 MJ3 CF1 CF2 
TA4 - 0.23 0.52 0.46 
MJ3 0.23 - 0.54 0.58 
CF1 0.52 0.54 - 0.31 
CF2 0.46 0.58 0.31 - 
Table 3. Beta diversity indices for each sample obtained by using Vegan Package in R. The B diversities shows that two CF 










Understanding the composition of the lung microbiome in CF patients pre- and post-CFTR 
treatment is of upmost significance in saving CF patient’s lives, further improving their treatment 
plan, and expanding the use of CFTR modulators by allowing the clinicans in better understanding 
the impact of the modulators on CF lungs. In this study, we used the novel Nanopore technology 
to perform metagenomic sequencing on two pediatric CF patients seeking care at Nemours 
Children’s Hospital pre-CFTR treatment with triple combination modulators. Nanopore MinION 
technology allowed us to obtain a comprehensive look into the lung microbiome by providing 
species level resolution at an unprecedentent level of detail. We then compared the findings in CF 
patients with two healthy individuals. We assessed the alpha diversity within each sample and the 
composition differences between each sample. Our findings detected P. aeruginosa, B. cenicepcia, 
H. Influenzia, and S. aureus in the lung microbiome of CF patients, with traditional bacteria 
expected to be seen in healthy lungs occupying the lung microbiome of the two healthy samples. 
Subsequently, comparing the alpha diversity indices supported the hypothesis that the microbial 
diversity is reduced among CF patients before the initiation of therapy compared to that of healthy 
controls. Understanding the differences in the lung composition of people with CF in comparison 
to healthy individuals, is significant in improving the quality of the care and treatment plan tailored 
for each CF patient. By interrogating the genomes of persistently carried bacteria collected before 
and after initiation CFTR treatment, we will be able to identify signatures of recent adaptation, 
which has implications for the treatment of all persons living with CF and will have direct 
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